JP2020533380A5 - - Google Patents

Info

Publication number

JP2020533380A5

JP2020533380A5 JP2020515138A JP2020515138A JP2020533380A5 JP 2020533380 A5 JP2020533380 A5 JP 2020533380A5 JP 2020515138 A JP2020515138 A JP 2020515138A JP 2020515138 A JP2020515138 A JP 2020515138A JP 2020533380 A5 JP2020533380 A5 JP 2020533380A5

Authority

JP

Japan

Prior art keywords

amino acid

acid sequence

combination drug

seq

drug according

Prior art date

2018-09-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 125000003275 alpha amino acid group Chemical group 0.000 claims 32
• 229940000425 combination drug Drugs 0.000 claims 22
• 102000025171 antigen binding proteins Human genes 0.000 claims 11
• 108091000831 antigen binding proteins Proteins 0.000 claims 11
• 239000003795 chemical substances by application Substances 0.000 claims 5
• 208000034578 Multiple myelomas Diseases 0.000 claims 4
• 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
• 101710112752 Cytotoxin Proteins 0.000 claims 2
• 206010028980 Neoplasm Diseases 0.000 claims 2
• 201000011510 cancer Diseases 0.000 claims 2
• 231100000599 cytotoxic agent Toxicity 0.000 claims 2
• 239000002619 cytotoxin Substances 0.000 claims 2
• 238000004519 manufacturing process Methods 0.000 claims 2
• 230000035772 mutation Effects 0.000 claims 2
• 238000011275 oncology therapy Methods 0.000 claims 2
• MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 208000023761 AL amyloidosis Diseases 0.000 claims 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
• 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
• 206010036673 Primary amyloidosis Diseases 0.000 claims 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims 1
• 239000000556 agonist Substances 0.000 claims 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
• 229960002204 daratumumab Drugs 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1